AEGLEA BIOTHERAPEUTICS INC (AGLE)
US00773J2024 - Common Stock
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief...
Aeglea BioTherapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β7 antibody,...
Aeglea BioTherapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...
Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...
Aeglea BioTherapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...
Aeglea BioTherapeutics to Participate in Upcoming September Conference
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...
Aeglea BioTherapeutics Announces Reverse Stock Split
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning!
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics...
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with best-in-class...
Aeglea stock initiated with Buy at Stifel (NASDAQ:AGLE)
Stifel launched its coverage on Aeglea BioTherapeutics (AGLE) with a Buy rating on Tuesday citing its potential against inflammatory bowel disorders. Read more here.
Aeglea BioTherapeutics Announces Grant of Inducement Awards
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc....
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for a final dive into the biggest pre-market stock movers this week as we check out what's happening on Friday!
Why Is Aeglea BioTherapeutics (AGLE) Stock Up 392% Today?
Aeglea BioTherapeutics (AGLE) stock is undergoing a massive rally on Thursday after it announced its acquisition of Spyre Therapeutics.
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
/PRNewswire/ -- Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other...
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics
Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD)...
Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial results for the first quarter 2023. First Quarter 2023 Financial Results...